Skip to main content
Image coming soon

GEN1584 Biotech Research Prioritization for Chief Science Officers

$199.00
Adding to cart… The item has been added

The Executive Diagnostic and Governance Toolkit

Biotech Research Prioritization for Chief Science Officers

Score your own function red, amber or green, find out which part is weakest, and walk into the next budget round able to defend what you want to fix. Built for leaders reviewing decide which research pipeline to prioritize for clinical trials and defend the choice to stakeholders.

$199 one-time
30-day money-back guarantee Verified against latest insights, updated access provided within 24h

Each order is checked and updated against the latest insights before delivery. That is why access takes up to 24 hours rather than being instant.

What you walk out with
A scored, ranked picture of your own function, and a defensible answer to what to fix first.
1 You stop guessing where you stand.
You finish with a score, not an opinion: every part of your function rated red, amber or green, with the weakest ranked first. Evidence: a Quick Scan for the shape of it, then seven domain assessments of 30 scored questions each, 210 in all, rolled into one scorecard, plus a maturity radar and a current-versus-target gap analysis.
2 You can defend the decision.
You walk into the budget round with the gap named, the owner named and done defined, instead of a case built on instinct. Evidence: project charter, scope statement, RACI, requirements traceability and work breakdown structure, pre-filled in your domain's language.
3 The work actually moves.
The month after the decision is already built, so nothing stalls waiting for someone to design a form. Evidence: more than 60 project templates across all five PMBOK process groups, plus runbooks, SOPs, a KPI framework, audit checklists and a risk matrix. 55 to 65 files in total.
4 You use it the day it lands.
No blank templates to interpret. Every workbook opens with what it is, who uses it, when, how, a 1 to 5 scoring guide, what good looks like, and a worked example you delete and type over.
The Quick Scan is one sitting. You will know your weakest area before the day is out.
Nothing in it is generic project management: the build rejects any file that could belong to another course. Updated after you enrol, so it reflects where the work stands now. The 144-chapter course is included behind it, for the parts you want to go deeper on.
Choosing the wrong research pipeline wastes years of effort and undermines stakeholder trust.

The situation this is built for

Every day, chief science officers face pressure to select one research pipeline over others—each with promising data, passionate advocates, and uncertain outcomes. The decision must balance scientific rigor, clinical feasibility, resource constraints, and strategic alignment. Without a consistent framework, these choices rely too heavily on intuition or incomplete data, leaving leaders vulnerable when questioned by executives, board members, or regulatory partners. The cost of a misstep is measured not just in dollars, but in delayed therapies and lost scientific momentum.

Who this is for

Chief science officers in biotechnology organizations who own pipeline selection and must defend those decisions in cross-functional leadership meetings and board reviews.

Who this is not for

This is not for lab managers, clinical operations staff, or external consultants who do not own the final decision on research prioritization.

What you walk away with

  • A standardized framework for comparing research pipelines
  • Clear documentation of decision criteria and trade-offs
  • Improved alignment between R&D and executive leadership
  • Greater confidence in go/no-go recommendations
  • Efficient integration of preclinical data into strategic decisions

How this maps to your situation

  • Assessing current decision processes
  • Identifying data gaps in pipeline evaluations
  • Aligning team members on evaluation criteria
  • Preparing for upcoming portfolio reviews

Before vs. after

Before
Decisions are inconsistent, data is siloed, and justifications rely on expert opinion rather than structured analysis.
After
Pipeline choices are made using a standardized, evidence-based framework with clear documentation and stakeholder alignment.

What's included with your purchase

  • 12 modules with 12 chapters each (144 chapters)
  • Downloadable templates and worked examples for every module
  • Hand-built implementation playbook delivered alongside course access
  • 30-day money-back guarantee

Delivery and format

  • Course and learning environment access provisioned within 24 hours of purchase
  • Hand-built implementation playbook delivered alongside course access

Format: Text-based modules and chapters in the Art of Service learning environment, plus downloadable templates and worked examples for every chapter, plus the hand-built implementation playbook delivered alongside course access.

Time investment: Approximately 3 hours per module, designed to be completed at your pace over 8–12 weeks, with immediate access to implementation tools.

If nothing changes
Continuing without a formal decision framework leads to repeated debates over criteria, delayed decisions, misaligned expectations, and increased vulnerability to challenges from board members or regulatory bodies—potentially resulting in years of misdirected R&D investment.

How this compares to the alternatives

Unlike general project management courses or scientific training programs, this course focuses exclusively on the decision architecture required for biotechnology pipeline prioritization—providing field-specific frameworks, real-world templates, and actionable playbooks tailored to the responsibilities of a chief science officer.

Also included: the full course, for when you want the reasoning behind a finding (12 modules, 144 chapters)

Depth reference. The diagnostic and the templates stand on their own; this is what to read when you want the reasoning behind a finding.

Module 1. Foundations of Pipeline Decision-Making
Establish the core principles and responsibilities inherent in selecting research pathways for clinical translation.
12 chapters in this module
  1. Understanding the role of the chief science officer in pipeline governance
  2. Mapping the lifecycle of a biotechnology research program
  3. Defining key decision points from discovery to clinical proposal
  4. Identifying internal and external stakeholders in pipeline reviews
  5. Recognizing common cognitive biases in research selection
  6. Balancing innovation potential with technical feasibility
  7. Aligning pipeline decisions with organizational mission and capacity
  8. Documenting assumptions behind early-stage research interpretations
  9. Setting expectations for data completeness in preclinical packages
  10. Integrating safety signals from in vitro and animal models
  11. Assessing novelty versus incremental advancement in target selection
  12. Creating a decision accountability framework for leadership
Module 2. Evaluating Therapeutic Mechanism Strength
Analyze the biological plausibility and target validation behind each candidate pathway.
12 chapters in this module
  1. Assessing target-disease association using genetic evidence
  2. Interpreting functional genomics data in target validation
  3. Evaluating on-target versus off-target effects in model systems
  4. Reviewing dose-response relationships in pharmacological assays
  5. Mapping pathway conservation across species for translatability
  6. Assessing redundancy in biological signaling networks
  7. Determining biomarker linkage to mechanism of action
  8. Evaluating target engagement data from biochemical assays
  9. Weighing evidence from loss-of-function versus gain-of-function studies
  10. Integrating CRISPR screening results into target confidence scores
  11. Assessing compensatory mechanisms in knockout models
  12. Documenting confidence levels in mechanistic hypotheses
Module 3. Assessing Preclinical Data Quality
Critically appraise the robustness and reproducibility of nonclinical study results.
12 chapters in this module
  1. Evaluating experimental design in animal efficacy studies
  2. Assessing statistical power and sample size justification
  3. Identifying signs of publication bias in literature reviews
  4. Reviewing blinding and randomization procedures in reports
  5. Detecting data dredging in biomarker correlation analyses
  6. Validating assay performance characteristics in study data
  7. Assessing batch-to-batch variability in compound synthesis
  8. Evaluating pharmacokinetic parameters for consistency
  9. Reviewing histopathology data with blinded interpretation
  10. Assessing duration of effect in chronic disease models
  11. Identifying overfitting in machine learning-based predictions
  12. Creating a data quality checklist for internal studies
Module 4. Clinical Feasibility and Trial Design Constraints
Determine the practical viability of moving a candidate into human testing.
12 chapters in this module
  1. Estimating first-in-human dosing from toxicology data
  2. Assessing route of administration challenges for novel modalities
  3. Evaluating formulation stability and shelf-life implications
  4. Determining patient recruitment feasibility for rare indications
  5. Mapping clinical endpoints to measurable biological changes
  6. Assessing monitoring requirements for safety-intensive therapies
  7. Reviewing comparator arm availability for trial design
  8. Evaluating duration of treatment in chronic conditions
  9. Assessing need for specialized clinical sites or equipment
  10. Identifying regulatory precedents for similar mechanisms
  11. Determining biomarker qualification status for use in trials
  12. Balancing endpoint sensitivity with real-world measurement
Module 5. Risk-Benefit Integration Across Modalities
Construct a unified assessment of potential benefit against safety and delivery risks.
12 chapters in this module
  1. Creating weighted scoring models for multi-parameter evaluation
  2. Integrating cytokine release risk into early safety profiles
  3. Assessing immunogenicity potential of biologic candidates
  4. Evaluating biodistribution patterns in tissue targeting
  5. Balancing potency against narrow therapeutic windows
  6. Incorporating off-tumor effects in oncology pipelines
  7. Assessing germline editing risks in gene therapy programs
  8. Mapping metabolic clearance pathways for toxicity risks
  9. Weighing long-term safety monitoring needs in trial planning
  10. Integrating reproductive toxicity findings into risk profiles
  11. Evaluating depot formation risks in sustained-release formulations
  12. Documenting risk mitigation strategies for high-concern liabilities
Module 6. Strategic Portfolio Context
Position individual pipeline candidates within the broader research and commercial landscape.
12 chapters in this module
  1. Mapping candidate alignment with company therapeutic focus
  2. Assessing competitive pipeline intelligence for timing decisions
  3. Evaluating freedom-to-operate considerations in target selection
  4. Analyzing patent life and exclusivity windows for development paths
  5. Assessing platform synergy across multiple programs
  6. Determining resource overlap in manufacturing infrastructure
  7. Evaluating platform scalability for future pipeline expansion
  8. Balancing platform investment against discrete product returns
  9. Assessing potential for combination therapy positioning
  10. Reviewing market access considerations in indication selection
  11. Evaluating orphan drug designation opportunities
  12. Assessing payer willingness to reimburse novel mechanisms
Module 7. Cross-Functional Decision Readiness
Prepare comprehensive dossiers that enable informed decisions across departments.
12 chapters in this module
  1. Structuring data packages for executive committee review
  2. Summarizing key uncertainties for leadership discussion
  3. Creating visual summaries of comparative pipeline performance
  4. Preparing Q&A briefs for board-level inquiries
  5. Aligning medical affairs input on unmet need definitions
  6. Incorporating regulatory affairs feedback on development paths
  7. Integrating biostatistics input on trial powering assumptions
  8. Reviewing CMC constraints with manufacturing leadership
  9. Assessing budget impact with finance stakeholders
  10. Documenting decision rationale for audit readiness
  11. Ensuring legal review of claims in decision documents
  12. Standardizing presentation formats across pipeline reviews
Module 8. Data Integration and Weight-of-Evidence Synthesis
Combine disparate sources of evidence into a coherent, defensible evaluation.
12 chapters in this module
  1. Applying GRADE principles to preclinical evidence grading
  2. Creating evidence maps for transparent data visualization
  3. Assigning confidence levels to different data types
  4. Resolving contradictions between in vitro and in vivo results
  5. Integrating real-world evidence into preclinical assessments
  6. Evaluating animal model limitations for human prediction
  7. Weighing case reports versus controlled study findings
  8. Assessing reproducibility across independent laboratories
  9. Incorporating negative data into overall assessments
  10. Using Bayesian reasoning to update confidence over time
  11. Documenting evidence gaps in candidate profiles
  12. Creating summary statements for non-scientific audiences
Module 9. Stakeholder Communication and Defense
Articulate and defend pipeline decisions to diverse audiences with varying levels of scientific literacy.
12 chapters in this module
  1. Translating mechanism of action for executive understanding
  2. Explaining risk-benefit trade-offs in non-technical terms
  3. Anticipating board questions about competitive positioning
  4. Presenting alternative scenarios in decision discussions
  5. Using analogies to explain complex biological concepts
  6. Preparing for challenges to data interpretation
  7. Communicating uncertainty without undermining confidence
  8. Aligning messaging across leadership spokespersons
  9. Responding to inquiries about failed predecessors
  10. Defining success criteria for early clinical milestones
  11. Explaining go/no-go thresholds to investor-facing teams
  12. Maintaining scientific integrity under commercial pressure
Module 10. Decision Governance and Review Cadence
Establish structured processes for ongoing pipeline evaluation and course correction.
12 chapters in this module
  1. Designing quarterly pipeline review meeting structures
  2. Setting data triggers for re-evaluation decisions
  3. Defining decision authority levels across stages
  4. Creating audit trails for major selection decisions
  5. Incorporating external advisory board input systematically
  6. Scheduling external benchmarking assessments
  7. Reviewing portfolio balance across therapeutic areas
  8. Assessing talent availability for specialized programs
  9. Evaluating infrastructure readiness for scale-up
  10. Updating risk profiles with new preclinical findings
  11. Incorporating regulatory feedback into go/no-go planning
  12. Managing sunset decisions for terminated pipelines
Module 11. Ethical and Societal Implications
Evaluate broader impacts of pipeline choices on patients, healthcare systems, and society.
12 chapters in this module
  1. Assessing equity in patient access to novel therapies
  2. Evaluating potential for therapeutic misconception in trials
  3. Considering long-term societal impact of gene editing
  4. Balancing aggressive timelines with thorough safety assessment
  5. Assessing environmental impact of manufacturing processes
  6. Evaluating dual-use potential of platform technologies
  7. Considering implications for germline transmission risks
  8. Addressing concerns about enhancement versus therapy
  9. Incorporating patient advocacy perspectives in selection
  10. Assessing global health relevance of indication choices
  11. Evaluating potential for medicalization of normal conditions
  12. Documenting ethical review considerations in decision logs
Module 12. Building Institutional Decision Capability
Institutionalize a repeatable, scalable process for future pipeline evaluations.
12 chapters in this module
  1. Creating standardized templates for pipeline dossiers
  2. Training team members on evidence grading frameworks
  3. Establishing data quality thresholds for advancement
  4. Documenting institutional risk tolerance profiles
  5. Developing onboarding materials for new science leaders
  6. Integrating decision frameworks into project management tools
  7. Creating archival systems for historical decision context
  8. Scheduling calibration sessions across research teams
  9. Implementing feedback loops from clinical outcomes
  10. Updating decision criteria based on portfolio experience
  11. Aligning performance metrics with long-term success
  12. Sustaining scientific rigor amid organizational growth

Frequently asked

Who is this course designed for?
This course is specifically designed for chief science officers who are responsible for selecting and justifying research pipeline advancement decisions in biotechnology organizations.
How is the course structured?
12 modules, each containing 12 chapters (144 chapters total).
Does this course cover clinical trial execution?
No, this course focuses on the decision to advance a pipeline to clinical trials, not on managing trials once initiated.
Are there live components or instructor access?
No, the course is self-paced and text-based, with downloadable resources and a tailored implementation playbook.
Can teams participate together?
Yes, the implementation playbook supports team adoption and cross-functional alignment.
What formats do the templates come in?
The implementation playbook downloads as PDF and editable XLSX. The course reads in your learning environment and exports to PDF for offline use. The files are yours to keep.
Can I share this with my team?
The licence is per person. Team pricing opens from three seats: reply to the order confirmation with TEAM and we will set it up.
How quickly can I start?
The diagnostic is one sitting and the templates work straight out of the kit. Account access takes up to 24 hours rather than being instant, because every order is checked and updated against the latest sources before it is delivered.
$199 one-time. Approximately 3 hours per module, designed to be completed at your pace over 8–12 weeks, with immediate access to implementation tools..

Within 24 hours your account in the learning environment is provisioned and the tailored implementation playbook is delivered alongside it.

30-day money-back guarantee·Know your weakest area today·210 scored questions·Course included· Account access within 24 hours
30-day money-back guarantee, no questions asked.
Thousands of organisations have bought from The Art of Service since 2000.